Background and aims:- CXCL5 is a small cytokine belonging to the
CXC chemokine family predominantly expressed on epithelial cells .
This cytokine stimulates the chemotaxis of neutrophils having
angiogenic properties. Small interfering RNAs or antibodies against
CXCL5 can suppress tumor growth.CXCL5 is considered a
therapeutic target in liver diseases. The aim of our study was to assess
CXCL5 serum levels in patients with chronic liver diseases.
Materials and Methods:- CXCL5 serum levels were measured in 60
patients with chronic liver disease and 20 apparently healthy controls.
Results:- Serum CXCL5 levels in patients with liver cirrhosis were
lower than in healthy controls, and correlated with the hepatic
biosynthetic capacity, Child-Pugh and MELD scores. In patients with
typical clinical complications of cirrhosis, CXCL5 levels were found
to be decreased. CXCL5 levels were correlated with clinical
presentation and laboratory parameters.
Conclusions:- serum CXCL5 levels are lower in patients with chronic
liver disease, suggesting that CXCL5 might be involved in the
pathogenesis of chronic liver disease. CXCL5 could serve as an
additional biomarker for hepatic necroinflammation and fibrosis.